Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF

R. Dummer, KT. Flaherty, C. Robert, A. Arance, JW. B de Groot, C. Garbe, HJ. Gogas, R. Gutzmer, I. Krajsová, G. Liszkay, C. Loquai, M. Mandalà, D. Schadendorf, N. Yamazaki, AD. Pietro, J. Cantey-Kiser, M. Edwards, PA. Ascierto

. 2023 ; 19 (16) : 1091-1098. [pub] 20230613

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy, komentáře

Perzistentní odkaz   https://www.medvik.cz/link/bmc23017084

WHAT IS THIS SUMMARY ABOUT?: Here, we summarize the 5-year results from part 1 of the COLUMBUS clinical study, which looked at the combination treatment of encorafenib plus binimetinib in people with a specific type of skin cancer called melanoma. Encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) are medicines used to treat a type of melanoma that has a change in the BRAF gene, called advanced or metastatic BRAF V600-mutant melanoma. Participants with advanced or metastatic BRAF V600-mutant melanoma took either encorafenib plus binimetinib together (COMBO group), compared with encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group). WHAT WERE THE RESULTS?: In this 5-year update, more participants in the COMBO group were alive for longer without their disease getting worse after 5 years than those in the VEMU and ENCO groups. Patients in the COMBO group were alive for longer without their disease getting worse when they: Had less advanced cancer Were able to do more daily activities Had normal lactate dehydrogenase (LDH) levels Had fewer organs with tumors before treatment After treatment, fewer participants in the COMBO group received additional anticancer treatment than participants in the VEMU and ENCO groups. The number of participants who reported severe side effects was similar for each treatment. The side effects caused by the drugs in the COMBO group decreased over time. WHAT DO THE RESULTS MEAN?: Overall, this 5-year update confirmed that people with BRAF V600-mutant melanoma that has spread to other parts of the body and who took encorafenib plus binimetinib were alive for longer without their disease getting worse than those who took vemurafenib or encorafenib alone. Clinical Trial Registration: NCT01909453 (ClinicalTrials.gov).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23017084
003      
CZ-PrNML
005      
20231026105408.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/fon-2022-1258 $2 doi
035    __
$a (PubMed)37309702
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dummer, Reinhard $u University Hospital Zurich, Zurich, Switzerland
245    10
$a COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF / $c R. Dummer, KT. Flaherty, C. Robert, A. Arance, JW. B de Groot, C. Garbe, HJ. Gogas, R. Gutzmer, I. Krajsová, G. Liszkay, C. Loquai, M. Mandalà, D. Schadendorf, N. Yamazaki, AD. Pietro, J. Cantey-Kiser, M. Edwards, PA. Ascierto
520    9_
$a WHAT IS THIS SUMMARY ABOUT?: Here, we summarize the 5-year results from part 1 of the COLUMBUS clinical study, which looked at the combination treatment of encorafenib plus binimetinib in people with a specific type of skin cancer called melanoma. Encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) are medicines used to treat a type of melanoma that has a change in the BRAF gene, called advanced or metastatic BRAF V600-mutant melanoma. Participants with advanced or metastatic BRAF V600-mutant melanoma took either encorafenib plus binimetinib together (COMBO group), compared with encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group). WHAT WERE THE RESULTS?: In this 5-year update, more participants in the COMBO group were alive for longer without their disease getting worse after 5 years than those in the VEMU and ENCO groups. Patients in the COMBO group were alive for longer without their disease getting worse when they: Had less advanced cancer Were able to do more daily activities Had normal lactate dehydrogenase (LDH) levels Had fewer organs with tumors before treatment After treatment, fewer participants in the COMBO group received additional anticancer treatment than participants in the VEMU and ENCO groups. The number of participants who reported severe side effects was similar for each treatment. The side effects caused by the drugs in the COMBO group decreased over time. WHAT DO THE RESULTS MEAN?: Overall, this 5-year update confirmed that people with BRAF V600-mutant melanoma that has spread to other parts of the body and who took encorafenib plus binimetinib were alive for longer without their disease getting worse than those who took vemurafenib or encorafenib alone. Clinical Trial Registration: NCT01909453 (ClinicalTrials.gov).
650    _2
$a lidé $7 D006801
650    _2
$a vemurafenib $x škodlivé účinky $7 D000077484
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    12
$a melanom $x farmakoterapie $x genetika $x patologie $7 D008545
650    12
$a nádory kůže $x farmakoterapie $x genetika $x patologie $7 D012878
650    12
$a nežádoucí účinky léčiv $x etiologie $7 D064420
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a mutace $7 D009154
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a komentáře $7 D016420
700    1_
$a Flaherty, Keith T $u Massachusetts General Hospital, Boston, MA, USA
700    1_
$a Robert, Caroline $u Gustave Roussy & Paris-Saclay University, Villejuif, France
700    1_
$a Arance, Ana $u Hospital Clinic of Barcelona & IDIBAPS, Barcelona, Spain
700    1_
$a B de Groot, Jan Willem $u Isala Oncology Center, Zwolle, The Netherlands
700    1_
$a Garbe, Claus $u University Hospital Tubingen, Tubingen, Germany
700    1_
$a Gogas, Helen J $u National & Kapodistrian University of Athens, Athens, Greece
700    1_
$a Gutzmer, Ralf $u Hannover Medical School, Hannover, & Ruhr-University Bochum, Minden Campus, Germany
700    1_
$a Krajsová, Ivana $u University Hospital Prague, Prague, Czech Republic
700    1_
$a Liszkay, Gabriella $u National Institute of Oncology, Budapest, Hungary
700    1_
$a Loquai, Carmen $u University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
700    1_
$a Mandalà, Mario $u University of Perugia, Perugia, Italy
700    1_
$a Schadendorf, Dirk $u University Hospital Essen, West German Cancer Center & German Cancer Consortium, Partner Site Essen, Essen, Germany
700    1_
$a Yamazaki, Naoya $u National Cancer Center Hospital, Tokyo, Japan
700    1_
$a Pietro, Alessandra di $u Pfizer, Milan, Italy
700    1_
$a Cantey-Kiser, Jean $u PharPoint Research, Durham, NC, USA
700    1_
$a Edwards, Michelle $u Formerly Pfizer, New York, NY, USA
700    1_
$a Ascierto, Paolo A $u Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
773    0_
$w MED00008687 $t Future oncology (London, England) $x 1744-8301 $g Roč. 19, č. 16 (2023), s. 1091-1098
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37309702 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105402 $b ABA008
999    __
$a ok $b bmc $g 2000551 $s 1203446
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 19 $c 16 $d 1091-1098 $e 20230613 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace